journal article
LitStream Collection
Issue Information
2024 Cancer
doi: 10.1002/cncr.34313pmid: N/A
No abstract is available for this article.
Home
doi: 10.1002/cncr.34313pmid: N/A
No abstract is available for this article.
Faraj, Kassem S.; Caram, Megan E. V.; Shahinian, Vahakn B.; Hollenbeck, Brent K.
doi: 10.1002/cncr.35379pmid: 38804732
Cancer treatment has become increasingly expensive, partially due to the use of specialty drugs. The costs of these drugs are often passed down to patients, who may face the consequences of paying for more than they can afford, leading to financial toxicity. The 340B drug pricing program is a health care policy that may provide an opportunity to mitigate the financial consequences of cancer care. The 340B program requires manufacturers to sell outpatient drugs at a discount to hospitals caring for a significant number of socioeconomically disadvantaged individuals. The program intended for hospitals to use savings from discounted purchases to expand their safety net to vulnerable patients. Some studies have shown that participating hospitals do this by offering more charity and discounted care, whereas others have demonstrated that hospitals fail to sufficiently expand their safety net. A potential flaw of the program is the lack of guidance from governing bodies on how hospitals should use savings from discounted purchases. There has been growing discussion among stakeholders to reform the 340B program given the mixed findings of its effectiveness. With the rising costs of specialty drugs and associated prevalence of financial toxicity in patients with cancer, there is an opportunity to address these issues through reform that improves the program. Directing hospitals to offer specific safety net opportunities, such as passing along discounted drug prices to vulnerable populations, could help the growing number of patients who are financially burdened by medications at the core of the 340B program.
Sedlack, Andrew J. H.; Varghese, Diana Grace; Naimian, Amirkia; Yazdian Anari, Pouria; Bodei, Lisa; Hallet, Julie; Riechelmann, Rachel P.; Halfdanarson, Thor; Capdevilla, Jaume; Del Rivero, Jaydira
doi: 10.1002/cncr.35463pmid: 39012928
Richardson, Noah H.; Taza, Fadi; Abonour, Rafat; Althouse, Sandra K.; Ashkar, Ryan; Abu Zaid, Mohammad; Hanna, Nassar H.; Kesler, Kenneth A.; Adra, Nabil; Einhorn, Lawrence H.
doi: 10.1002/cncr.35375pmid: 38768296
Showing 1 to 10 of 20 Articles
Neuroendocrine neoplasms are a diverse group of neoplasms that can occur in various areas throughout the body. Well‐differentiated neuroendocrine tumors (NETs) most often arise in the gastrointestinal tract, termed gastroenteropancreatic neuroendocrine tumors (GEP‐NETs). Although GEP‐NETs are still uncommon, their incidence and prevalence have been steadily increasing over the past decades. The primary treatment for GEP‐NETs is surgery, which offers the best chance for a cure. However, because GEP‐NETs are often slow‐growing and do not cause symptoms until they have spread widely, curative surgery is not always an option. Significant advances have been made in systemic and locoregional treatment options in recent years, including peptide‐receptor radionuclide therapy with α and β emitters, somatostatin analogs, chemotherapy, and targeted molecular therapies.